NeoGenomics

Traded on the St. Petersburg Stock Exchange
NeoGenomics Laboratories, Inc. is a high-complexity CLIA-certified clinical laboratory, pharma services and information services company that specializes in cancer genetics diagnostic testing.
NeoGenomics stock price chart
-81%
P/E adj.
Net profit (adj.)
P/B
Book value
P/FCF
FCF
Yield
Growth potential

NeoGenomics balance sheet

Report period2016 2017 2018 2019 2020 2021
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

NeoGenomics cash flows

Report period2016 2017 2018 2019 2020 2021
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
Adjusted Earnings
EBITDA
Adjusted EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS
Adjusted EPS

NeoGenomics multipliers

Report period2016 2017 2018 2019 2020 2021
P/E
P/E adj.
E/P
E adj./P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
Net Debt/EBITDA adj.
EV/EBITDA
EV/EBITDA adj.

NeoGenomics profitability

Report period2016 2017 2018 2019 2020 2021
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
NeoGenomics assets
NeoGenomics cash flows

NeoGenomics shares

TickerNameTypeNominal valueISINPrice
NEO:USNeoGenomics, Inc.Common share-US64049M2098$8.92
NeoGenomics news
27.04.2022
NeoGenomics' GAAP loss for 3 months of 2022 was $49.408 million, up 2.3 times from $22.114 million in the previous year. Revenue increased 1.4% to $117.169 million from $115.533 million a year earlier.
23.02.2022
Net income of NeoGenomics under GAAP for 2021 was $8.347 million, compared to a profit of $4.172 million in the previous year. Revenue increased 9% to $484.329 million from $444.448 million a year earlier.
04.11.2021
NeoGenomics' GAAP net income for 9M 2021 was $33.412 mln, against a loss of $11.245 mln in the previous year. Revenue increased 12.6% to $358.597 million from $318.451 million a year earlier.
06.08.2021
NeoGenomics' GAAP net income for six months of 2021 was $53.759 million, compared to a loss of $13.802 million in the previous year. Revenue increased 22.9% to $237.257 million from $193.007 million a year earlier.
General information
Company nameNeoGenomics
SectorHealth Care / Health Care Equipment & Services / Health Care Providers & Services / Health Care Services
Business address12701 COMMONWEALTH DRIVE SUITE 9 FORT MYERS FL 33913 9419231949
Mailing address12701 COMMONWEALTH DRIVE SUITE 9 FORT MYERS FL 33913
Websitewww.neogenomics.com
Information disclosurewww.sec.gov